Maximus (NYSE:MMS) Stock Rating Lowered by Wall Street Zen

Maximus (NYSE:MMS) was downgraded by equities researchers at Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Monday.

Several other brokerages also recently weighed in on MMS. Weiss Ratings restated a “buy (b-)” rating on shares of Maximus in a research note on Monday, December 29th. Zacks Research upgraded Maximus from a “hold” rating to a “strong-buy” rating in a report on Tuesday, December 30th. One analyst has rated the stock with a Strong Buy rating and one has assigned a Buy rating to the stock. According to MarketBeat, Maximus has an average rating of “Strong Buy”.

Maximus Trading Down 1.5%

NYSE:MMS opened at $73.76 on Monday. The company’s 50 day moving average is $88.14 and its 200-day moving average is $86.67. The company has a quick ratio of 2.34, a current ratio of 2.34 and a debt-to-equity ratio of 0.88. Maximus has a 12 month low of $63.77 and a 12 month high of $100.00. The firm has a market cap of $4.02 billion, a price-to-earnings ratio of 11.23 and a beta of 0.56.

Maximus (NYSE:MMS) last posted its earnings results on Thursday, February 5th. The health services provider reported $1.85 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.84 by $0.01. The business had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.37 billion. Maximus had a net margin of 6.92% and a return on equity of 25.30%. Maximus’s revenue was down 4.1% compared to the same quarter last year. During the same period last year, the business posted $1.61 EPS. Maximus has set its FY 2026 guidance at 8.050-8.350 EPS. Equities analysts anticipate that Maximus will post 6.15 EPS for the current year.

Insider Activity at Maximus

In other news, CFO David Mutryn bought 1,000 shares of Maximus stock in a transaction that occurred on Monday, February 9th. The stock was purchased at an average cost of $75.62 per share, with a total value of $75,620.00. Following the completion of the transaction, the chief financial officer directly owned 40,037 shares in the company, valued at $3,027,597.94. This trade represents a 2.56% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Bruce Caswell purchased 3,175 shares of the firm’s stock in a transaction on Tuesday, February 10th. The shares were acquired at an average price of $78.45 per share, for a total transaction of $249,078.75. Following the purchase, the chief executive officer directly owned 328,013 shares of the company’s stock, valued at approximately $25,732,619.85. This represents a 0.98% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last ninety days, insiders bought 4,231 shares of company stock worth $329,521. 1.80% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in MMS. Dimensional Fund Advisors LP boosted its holdings in Maximus by 5.2% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,965,916 shares of the health services provider’s stock valued at $169,700,000 after purchasing an additional 96,343 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Maximus by 0.3% during the 4th quarter. Geode Capital Management LLC now owns 1,482,079 shares of the health services provider’s stock worth $127,952,000 after buying an additional 5,130 shares during the period. Boston Partners boosted its stake in Maximus by 47.0% in the 3rd quarter. Boston Partners now owns 966,139 shares of the health services provider’s stock valued at $88,236,000 after buying an additional 308,892 shares in the last quarter. Reinhart Partners LLC. boosted its stake in Maximus by 0.8% in the 3rd quarter. Reinhart Partners LLC. now owns 921,578 shares of the health services provider’s stock valued at $84,206,000 after buying an additional 7,722 shares in the last quarter. Finally, Stephens Investment Management Group LLC grew its position in Maximus by 49.0% in the third quarter. Stephens Investment Management Group LLC now owns 720,943 shares of the health services provider’s stock valued at $65,873,000 after acquiring an additional 237,097 shares during the period. Institutional investors and hedge funds own 97.21% of the company’s stock.

About Maximus

Maximus, Inc (NYSE: MMS) is a global provider of government services focused on delivering health and human services programs. The company partners with federal, state, and local agencies to administer and manage programs that support individuals and families across various stages of life. Key service areas include eligibility determination and enrollment services for Medicaid, Medicare, Children’s Health Insurance Program (CHIP) and other public assistance programs, as well as call center operations, case management and program integrity solutions.